Hypertension - Drug Pipeline Landscape, 2023

Hypertension - Drug Pipeline Landscape, 2023

Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side effects of drugs etc).

The most common causes of Hypertension include underlying diseases, side effects of medications, age, overweight, genetics, high sodium intake, alcohol consumption, stress, lifestyle, pregnancy.

Symptoms include shortness of breath, early morning headaches, nose bleeding, irregular heart rhythms, fatigue, nausea, vomiting, confusion, anxiety, chest pain, and muscle tremors. Most people with high blood pressure have no signs or symptoms of it, hence given name as "silent killer".

Hypertension can be diagnosed if the systolic blood pressure readings are greater than or equal to 140 mmHg and/or the diastolic blood pressure readings are greater than or equal to 90 mmHg measured on two different days.

The most common treatments for Hypertension are vasodilators, renin inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, alpha/beta blockers, diuretics, and/or lifestyle changes such as physical activity, healthy salt diet.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Hypertension treatment such as IN-C008, Yutrepia, Aprocitentan, MK-5475, Ralinepag and others. Key players involved in the development of therapies to treat Hypertension are HK inno.N Corporation, Liquidia Technologies Inc, Idorsia Pharmaceuticals Ltd, Merck Inc, United Therapeutics and others. Three drugs are under late-stage Pre-Registration, thirty-eight drugs are under Phase III clinical trials, thirty-three drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical, Discovery and Unknown stages of development.

In December 2022, Idorsia Pharmaceuticals Ltd submitted a New Drug Application to the US FDA for Aprocitentan for the treatment of patients with difficult-to control (resistant) hypertension.

Report Highlights

Global Insight Service's, Hypertension - Drug Pipeline Landscape, 2023 report provides an overview of the Hypertension pipeline drugs. This report covers detailed insights on Anti-hypertension drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Anti-hypertension pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.